Abstract 4389: HJ-093, a novel, orally bioavailable, and potent pan-RAS inhibitor, for the treatment of various RAS mutation-driven cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4389
Abstract: RAS mutations dominate tumorigenesis as they account for approximately 30% of human cancer cases, and are common in various solid tumor types such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal… read more here.
Keywords: cancer; ras mutation; various ras; potent pan ... See more keywords